TapewireFind a company

person · Reporting owner

LaBarre Michael J.

Disclosed activity across 1 company

Tapewire entity
82745
SEC CIK
0001507174

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
HALOZYME THERAPEUTICS, INC.HALO · Entity 793SVP, CHIEF TECHNICAL OFFICERFebruary 25, 2025February 27, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HALOZYME THERAPEUTICS, INC.

Report date February 25, 2025 · Filed February 27, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect173,756 Ending reported balance After 2025-02-27 transaction · row 6
6 source rows · reconciled sequence

Row 1 · 2025-02-25 · Sale · Disposed 9,300 · Balance 186,153

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 2 · 2025-02-25 · Sale · Disposed 700 · Balance 185,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2025-02-26 · Sale · Disposed 9,400 · Balance 176,053

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2025-02-26 · Sale · Disposed 600 · Balance 175,453

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2025-02-27 · Sale · Disposed 1,597 · Balance 173,856

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2025-02-27 · Sale · Disposed 100 · Balance 173,756

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024.

F2: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.54 to $58.47. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.54 to $58.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.62 to $58.61. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: Represents a weighted average sales price per share. These shares were sold at prices ranging from $58.62 to $58.68. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: Represents a weighted average sales price per share. These shares were sold at prices ranging from $57.71 to $58.66. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 20, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $61.06 $610,550.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $60.65 to $61.51. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
August 20, 2024 Filed Aug 21, 2024 22:03 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $16.65 $166,500.00
Disclosure

SEC source: 0001415889-24-021850 · form4-08212024_100827.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
July 24, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 8,285 $0.00 Strike: $16.65 $0.00
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 9

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,861

Underlying: Common Stock · 10,000 shares

Expires 2029-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F6 · derivative.exercise_date: This option was granted on February 12, 2019 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
July 24, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 1,715 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
July 24, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $55.12 $551,150.00
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.89 to $55.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 24, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,285 $16.65 $137,945.25
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
July 24, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 1,715 $8.11 $13,908.65
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,891

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
July 23, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
July 23, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 5,291 $55.27 $292,407.12
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $55.08 to $55.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 23, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 4,709 $54.46 $256,466.27
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 173,467

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $54.05 to $54.97. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
July 23, 2024 Filed Jul 24, 2024 21:48 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-020055 · form4-07242024_090711.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 20:17 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-017625 · form4-06202024_080605.xml · derivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 20:17 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $49.43 $494,260.00
Disclosure

SEC source: 0001415889-24-017625 · form4-06202024_080605.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.00 to $49.74. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 18, 2024 Filed Jun 20, 2024 20:17 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-017625 · form4-06202024_080605.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
May 22, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
May 22, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $45.38 $453,840.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $45.20 to $45.55. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 22, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
May 21, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
May 21, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $45.16 $451,640.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $44.785 to $45.455. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
May 21, 2024 Filed May 22, 2024 21:24 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-014123 · form4-05222024_090507.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
April 17, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
April 17, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $38.49 $384,890.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
April 17, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
April 16, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,715

Underlying: Common Stock · 10,000 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
April 16, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $38.35 $383,500.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 168,176

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
April 16, 2024 Filed Apr 17, 2024 23:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $8.11 $81,100.00
Disclosure

SEC source: 0001415889-24-011058 · form4-04172024_110437.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 2,890 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,715

Underlying: Common Stock · 2,890 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 292 $0.00 Strike: $16.78 $0.00
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 292 shares

Expires 2028-07-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option was granted on July 2, 2018 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 8,436 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · derivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,436 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 2,890 $8.11 $23,437.90
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 168,176

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: Represents an acquisition of 2,890 shares by the Reporting Person pursuant to a cash exercise and hold transaction.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 292 $16.78 $4,899.76
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Represents an acquisition of 292 shares by the Reporting Person pursuant to a cash exercise and hold transaction.

Read SEC document
March 26, 2024 Filed Mar 26, 2024 23:38 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 8,436 $12.07 $101,822.52
Disclosure

SEC source: 0001415889-24-009158 · form4-03262024_110343.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Represents an acquisition of 8,436 shares by the Reporting Person pursuant to a cash exercise and hold transaction.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 3,551 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 8

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,605

Underlying: Common Stock · 3,551 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 6,449 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 7

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,436

Underlying: Common Stock · 6,449 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $42.27 $422,730.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,558

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $42.00 to $42.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 3,551 $8.11 $28,798.61
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
March 13, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 6,449 $12.07 $77,839.43
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 163,007

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 10,000 $0.00 Strike: $12.07 $0.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,885

Underlying: Common Stock · 10,000 shares

Expires 2027-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · derivative.exercise_date: This option was granted on February 22, 2017 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $41.64 $416,370.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,558

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $41.26 to $42.035. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 21:22 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 10,000 $12.07 $120,700.00
Disclosure

SEC source: 0001415889-24-007825 · form4-03132024_090313.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 166,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionOption to Purchase Common Stock · Derivative 7,471 $0.00 Strike: $8.11 $0.00
Disclosure

SEC source: 0001415889-24-005756 · form4-02282024_110246.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,156

Underlying: Common Stock · 7,471 shares

Expires 2026-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F5 · derivative.exercise_date: This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 7,471 $39.54 $295,418.28
Disclosure

SEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,558

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.37 to $39.80. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionCommon Stock 7,471 $8.11 $60,589.81
Disclosure

SEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 3

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

Read SEC document
February 28, 2024 Filed Feb 28, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 2,529 $39.56 $100,044.71
Disclosure

SEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,558

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.40 to $39.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 27, 2024 Filed Feb 28, 2024 23:49 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 SaleCommon Stock 10,000 $39.95 $399,460.00
Disclosure

SEC source: 0001415889-24-005756 · form4-02282024_110246.xml · nonDerivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,087

F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.

F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $39.757 to $40.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 22:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantRestricted Stock Units · Derivative 18,985 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-24-005547 · form4-02272024_100206.xml · derivative · entry 2

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,985

Underlying: Common Stock · 18,985 shares

Expires not disclosed

F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

Read SEC document
February 23, 2024 Filed Feb 27, 2024 22:12 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 GrantOption to Purchase Common Stock · Derivative 19,674 $0.00 Strike: $40.56 $0.00
Disclosure

SEC source: 0001415889-24-005547 · form4-02272024_100206.xml · derivative · entry 1

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,674

Underlying: Common Stock · 19,674 shares

Expires 2034-02-23

F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 4,264 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · derivative · entry 6

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,789

Underlying: Common Stock · 4,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Exercise / conversionRestricted Stock Units · Derivative 6,112 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · derivative · entry 5

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,224

Underlying: Common Stock · 6,112 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Read SEC document
February 16, 2024 Filed Feb 20, 2024 23:59 UTC HALOZYME THERAPEUTICS, INC. HALO · Entity 793 Tax withholdingCommon Stock 2,160 $36.10 $77,976.00
Disclosure

SEC source: 0001415889-24-004477 · form4-02202024_110252.xml · nonDerivative · entry 4

LaBarre Michael J. · CIK 0001507174 · SVP, CHIEF TECHNICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,087

F2 · shares: The reported disposition of 2,160 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.